Advertisement: Cambridge Network mid banner
18 June, 2022 - 03:03 By Tony Quested

New CEO for Evonetix as company prepares to commercialise DNA synthesis platform

Cambridge synthetic biology company Evonetix, which is bringing semiconductor technology to DNA synthesis, has ended a long wait for a new CEO by hiring Colin McCracken from Fludigm Corp in San Francisco.

It is now 14 months since founding CEO Tim Brears left Evonetix. Matthew Hayes, who has been interim CEO, will resume his role as chief technology officer following an orderly transition.

Evonetix says McCracken’s appointment will support the next phase of the company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.

McCracken brings over 20 years’ experience in commercial and business development roles. He was senior VP and chief commercial officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the company’s global reach. 

He has delivered commercial success in numerous leadership positions, including Vice President and General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President and Head of European Sales at Life Technologies and National Sales Manager at Qiagen.

As CEO of Evonetix, Colin will focus on building strategic partnerships and customer relationships, ahead of the commercial introduction of the company’s first product, a benchtop DNA printer. 

The announcement comes as Evonetix continues to strengthen its senior leadership team, following the recent appointment of Paul Beastall as chair, as the company enters the next phase of its development, moving from pure research and development into product commercialisation.

McCracken said: “The team at Evonetix has achieved major milestones in building the technology to enable semiconductor based decentralised DNA synthesis. 

“The company’s technology has the potential to revolutionise synthetic biology, overcoming the limitations of centralised supply by making rapid synthesis of complex DNA libraries and genes routine in every lab. 

“It is an honour to join Evonetix at this pivotal point in their development and I’m looking forward to working with the team to execute our vision and commercial strategy.”

Dr Matthew Hayes, CTO and founder at Evonetix, added: “We have engaged in an extensive and detailed search to find the right person to lead Evonetix into our next phase of development. 

‘Colin has impressed us with both his commercial knowledge and ability to relate to the leadership team and wider organisation. We are all looking forward to working with him and continuing to build Evonetix’s future.”

Newsletter Subscription

Stay informed of the latest news and features